Study GZMG is a multicenter, Phase 2 study designed to evaluate the efficacy and safety of brenipatide as an adjunctive treatment to BUP±NX, in participants with OUD who are in early recovery. The purpose of this study is to assess the efficacy and safety of brenipatide at different dose levels (0.3 mg, 0.75 mg, and 1.5 mg once weekly) compared with placebo as an adjunctive treatment to BUP±NX, in participants with OUD who are in early recovery.THIS STUDY IS ENROLLING BY INVITATION ONLY - The study will enroll participants from 18 to 75 years of age, inclusive, who have OUD. To be eligible, participants must have tested positive for opioids (other than buprenorphine) at least once either during the screening or within the past 30 days before screening, as confirmed by buprenorphine provider. Participants must have also been taking transmucosal buprenorphine within a generally optimized dose range of 16-32 mg/day for 8 to 52 weeks before screening. Study participants will be excluded based on conditions that could interfere with study assessments or increase a participant’s risk of experiencing side effects during the study.

The goal of this clinical study is to generate data on the intended use of a chlorhexidine gluconate (CHG)-impregnated antimicrobial incise drape. The study includes subjects undergoing primary hip or knee arthroplasty procedures.THIS STUDY IS ENROLLING BY INVITATION ONLY - The Principal Investigator (Dr. Buller) and / or Dr. Sonn will review the medical records to initially identify potential subjects, mention study to patients in their pre-operative clinic visit who meet/likely meet screening criteria, ascertain interest, and inform the key personnel about patients who are interested in learning more about the study.

The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).THIS STUDY IS ENROLLING BY INVITATION ONLY

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding induction chemotherapy to the usual treatment of chemotherapy and radiation followed by maintenance may be more effective in treating patients with high risk, locally advanced cervical cancer.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.The main goals of this study are to:Evaluate the efficacy of BMS-986489 vs durvalumabEvaluate the safety profile of BMS-986489Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials OfficeEmail: iutrials@iu.eduPhone: (317) 278-5632

The purpose of this study is to investigate the effect of balcinrenone/dapagliflozin compared with dapagliflozin, on the risk of CV death, HF event with and without hospitalization, in patients with chronic HF, impaired kidney function, and who have had a recent HF event.THIS STUDY IS ENROLLING BY INVITATION ONLY

Researchers as the Indiana University Simon Comprehensive Cancer Center are conducting a study to research the safety and effectiveness of increasing doses of CD4CAR T cell therapy for patients who have been diagnosed with, or are being treated for, relapsed or refractory (has not responded to treatment) CD4+ chronic myelomonocytic leukemia (CMML).  CD4+ CMML is a blood cancer that affects white blood cells that express the protein CD4. The CD4CAR therapy is designed to bind to and eliminate cells, including cancer cells that have this protein.  We will evaluate up to 5 different dose levels of CD4CAR T cells and study what side effects occur with these dose levels.  We will also evaluate how effective the dose levels are at treating cancer in the participants in this study.  This therapy is considered investigational which means it has not been approved by the Food and Drug Administration (FDA) as treatment for your.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632